Periodic Versus Continuous IV Iron Supplementation in HD Patients
Phase 4
Completed
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Registration Number
- NCT02787824
- Lead Sponsor
- Papageorgiou General Hospital
- Brief Summary
The purpose of this study was to compare the efficacy of two regimens of intravenous iron sucrose \[continuous (in every hemodialysis session) versus intermittent (every 1-4 weeks)\] on the response of rHuEPO in the maintenance phase of its administration in hemodialysis patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- Constant rHu-EPO and iron dose for at least 2 months before starting the study
- Hemoglobin ≥ 8,5g/dl and <12,5 g/dl
- Ferritin < 1000 mg/dl
- TSAT < 50%
- CRP < 5 mg/dl
Exclusion Criteria
- Malignant tumor disease
- Oral iron supplementation
- Active bleeding issues
- Surgical intervention within the last 8 weeks before study inclusion
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description continuous iv administration of iron sucrose Iron Sucrose Supplement Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session). intermittent iv administration of iron sucrose Iron Sucrose Supplement Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
- Primary Outcome Measures
Name Time Method Change of serum hemoglobin level (g/dl) Month 0, 1, 2, 3, 4
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Papageorgiou General Hospital
🇬🇷Thessaloniki, Greece